Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.

@article{Porst2012ChronicPI,
  title={Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.},
  author={Hartmut Porst and Katja Hell-Momeni and Hartwig B{\"u}ttner},
  journal={Expert opinion on pharmacotherapy},
  year={2012},
  volume={13 10},
  pages={1481-94}
}
INTRODUCTION Tadalafil distinguishes itself from other available phosphodiesterase type 5 (PDE-5) inhibitors by its half-life of ∼ 17.5 h, which results in erectile responsiveness for up to 36 h after a single dose. Most clinical experience has been reported with on-demand use of PDE-5 inhibitors, but several studies have been able to demonstrate that tadalafil, given once-daily in low doses, is both highly effective and well tolerated. AREAS COVERED This paper reviews the current evidence… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver • 2015

References

Publications referenced by this paper.
Showing 1-10 of 77 references

Similar Papers

Loading similar papers…